Triana Biomedicines is a biotechnology startup in Boston. As an RA Capital portfolio company, Triana is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated the best-in-class platform and initiated multiple programs across different disease areas. The therapeutic approach pioneered by Triana Bio has the potential to fundamentally change the paradigm of drug discovery and bring significant clinical benefits to patients.